If you look at the company’s income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, NVAX earned gross profit of 15.67 Million, in 2015 0 gross profit, while in 2016 Novavax, Inc. The stock traded with the volume of 4.08 Million shares in the last trading session.

The Company has 289.87 million shares outstanding and 278.43 million shares were floated in market.

The relative strength index or RSI highlights overbought (above 70) and oversold (below 30) areas. The RSI oscillates between zero and 100. The current value of the RSI is 56.73 that is neither bought nor sold range. (NVAX) is at 39.33.

To stay one step ahead we extended our research by comparing different price targets. This is the price at which the trader or investor wants to exit his existing position so he can realize the most reward. Currently, the stock has a 1 Year Price Target of $3.58. They now have a Dollars 25 price target on the stock. They now have a Dollars 14 price target on the stock.

In recent action, Novavax, Inc. During the same quarter a year ago, the company earned ($0.29) EPS. Consensus earnings estimates are far from flawless, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. The difference between Actual EPS and Estimated EPS was 0.02 Percent.

By historical standards, Novavax, Inc. remains a cheap stock. The stock touched its high share price of $8.49 on 09/15/16 and the stock also touched its Lowest price in the last 52-weeks of trading on 05/05/17 as $0.73. Analysts are forecasting earnings of $-0.16 on a per share basis this quarter. The count of Hold ratings in that period was 7. The firm had revenue of $5.68 million for the quarter, compared to the consensus estimate of $6.17 million. The stock is expected to report revenue as high as $6.5M and as low as $4.5M per share.

09/16/2016 – Novavax, Inc. was downgraded to “neutral” by analysts at JP Morgan. There are advantages to using a moving average in your trading, as well options on what type of moving average to use. The average P/E ratio of 60.13 times earnings. With its share price languishing below $1, though, the company is in danger of delisting from the NASDAQ exchange. While the company’s share hit the 52 week high on 09/15/16 stationing the value of $8.49. The stock appeared -64.85% below its 52-week highs and is up 77.45% for the last five trades.

In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision.

Zacks Investment Research also rated the stock with a value of 2.71.

In an overview of the current analyst recommendations, Buy count is 1 and Overweight is 0 while the number of analysts recommending Sell and Underweight are 0 and 0, respectively.

A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. Following the completion of the transaction, the insider now owns 128,279 shares of the company’s stock, valued at $107,754.36. UBS Asset Management Americas Inc. boosted its stake in Novavax by 4.3% in the third quarter.

Novavax, Inc. (NVAX) is now showing its ROA (Return on Assets) of -56.8%.